Antibody Solutions Becomes Approved CRO for Leveragen’s Singularity Sapiens Mouse

SANTA CLARA, Calif.--(BUSINESS WIRE)--Antibody Solutions, a leading provider of custom antibody services to the biopharmaceutical market, announced today that it has been approved as a contract research organization (CRO) for use of the next-generation fully human single-domain antibody platform – the Singularity Sapiens Mouse – by Boston-based Leveragen, Inc. The agreement allows Antibody Solutions to pursue antibody discovery initiatives using Leveragen mice for clients who have licensed the proprietary platform from Leveragen, and expands the repertoire of human antibody-producing transgenic animals that Antibody Solutions’ experts can leverage for client discovery programs.

Released in 2024, the Singularity Sapiens Mouse platform was developed to provide antibody researchers an effective way around some of the inherent challenges with conventional transgenic animal models, including restricted antibody diversity and suboptimal immune responses. The mice exclusively generate heavy chain antibodies through a targeted approach that both ensures faithful expression of human immunoglobulin genes and eliminates interfering conventional antibodies.

“We don’t actively embrace a technology that’s pushing at the boundaries unless we see the clear value in it for our clients. And we see precisely that value in the Singularity Sapiens Mouse platform,” said Antibody Solutions Co-Founder and CEO John Kenney, PhD. “It represents a pioneering approach to heavy chain antibody discovery, and yet it’s already demonstrated its effectiveness in promoting optimal B cell development and robust immune responses. It’ll be an ideal complement to the other transgenic platforms we deploy, and we expect it to open up some exciting new discovery options, especially for our clients pursuing alternative therapeutic modalities like single-domain or bi-specific antibodies.”

"We are pleased to welcome Antibody Solutions as an approved CRO for the Singularity Sapiens Mouse platform," said Dr. Weisheng Chen, Founder and CEO of Leveragen. "Our selection process emphasizes partners with a proven track record of excellence, deep expertise in antibody discovery, and a shared commitment to advancing innovation—qualities that Antibody Solutions exemplifies through their strong infrastructure and broad industry connections. This collaboration will broaden access to the Singularity Sapiens platform, driving the accelerated discovery of modular, fully human single-domain antibodies that meet the highest standards for therapeutic development.”

About Antibody Solutions

Antibody Solutions helps biopharmaceutical companies advance their discovery of better therapeutics and diagnostics by delivering fit-for-purpose antibodies. Using its Cellestive antibody discovery platform, the company provides comprehensive project management and technical support in a fee-for-service, pay-as-you-go business model. Antibody Solutions has served more than 800 clients, including the top 10 global pharmaceutical companies, and can boast a 96% client return rate. Founded in 1995, the company is headquartered in Santa Clara, CA and serves clients worldwide. Learn more at antibody.com.

About Leveragen

Leveragen is a Boston-based genetic engineering company developing next-generation mouse models for antibody discovery. Leveragen’s flagship platform, the Singularity Sapiens Mouse, exclusively generates heavy chain antibodies from the complete human VH repertoire integrated into the modified mouse Igh locus. This targeted approach safeguards gene regulation and abolishes interference from conventional antibodies, promoting optimal B cell development and robust immune responses. Consequently, the derived fully human single-domain antibodies (sdAbs) exhibit superior diversity, affinity, stability, solubility, modularity, and functionality. The compact size and modular structure of sdAbs make them exceptionally versatile for constructing a broad range of biologics, including multispecific and multivalent antibodies, antibody drug conjugates, as well as key components for mRNA and cell therapies. Learn more at leveragen.com.